EP HIV-1090: EPMN will begin in 4 to 6 weeks a double-blind, placebo-controlled, U.S. Phase I/II dose-escalation study of its EP HIV-1090 in about 40 HIV-1 infe

Epimmune Inc. (EPMN), San Diego, Calif.
Product: EP HIV-1090

Read the full 93 word article

How to gain access

Continue reading with a
two-week free trial.